Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Merck must face trial on a Black IT director’s claims that racial bias drove his firing after he ordered the removal of a White contractor from a project, a New York federal judge ruled.

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

Merck & Co Inc (MRK) stock saw a modest uptick, ending the day at $98.28 which represents a slight increase of $0.83 or 0.85% from the prior close of $97.45. The stock opened at $97.42 and touched a ...

Disclosed in the latest SEC filing, a significant insider purchase on January 29, involves Chirfi Guindo, Chief Marketing Officer at Merck & Co MRK.

What Happened: In a recent Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday, Oosthuizen increased their investment in Merck & Co by purchasing 8,664 shares through ...

Merck said the Phase 3 "Hyperion" study, which was evaluating Winrevair versus placebo in recently diagnosed adults with PAH at intermediate or high risk of disease progression, had lost clinical ...

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

Bank of America Securities analyst Tim Anderson reiterated a Buy rating on Merck & Company (MRK – Research Report) today and set a price ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...